BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24722062)

  • 1. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
    Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
    Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
    Lotan TL; Torres A; Zhang M; Tosoian JJ; Guedes LB; Fedor H; Hicks J; Ewing CM; Isaacs SD; Johng D; De Marzo AM; Isaacs WB
    Oncotarget; 2017 Apr; 8(14):22772-22782. PubMed ID: 28186998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men.
    Heise M; Jarzemski P; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Haus O
    Pol J Pathol; 2019; 70(2):127-133. PubMed ID: 31556563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
    Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
    BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.
    Karlsson R; Aly M; Clements M; Zheng L; Adolfsson J; Xu J; Grönberg H; Wiklund F
    Eur Urol; 2014 Jan; 65(1):169-76. PubMed ID: 22841674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Interaction of
    Sipeky C; Gao P; Zhang Q; Wang L; Ettala O; Talala KM; Tammela TLJ; Auvinen A; Wiklund F; Wei GH; Schleutker J
    Clin Cancer Res; 2018 Dec; 24(24):6265-6276. PubMed ID: 30181389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.
    Breyer JP; Avritt TG; McReynolds KM; Dupont WD; Smith JR
    Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1348-53. PubMed ID: 22714738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.
    Beebe-Dimmer JL; Isaacs WB; Zuhlke KA; Yee C; Walsh PC; Isaacs SD; Johnson AM; Ewing CE; Humphreys EB; Chowdhury WH; Montie JE; Cooney KA
    BJU Int; 2014 May; 113(5):830-5. PubMed ID: 24148311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.
    Schroeck FR; Zuhlke KA; Siddiqui J; Siddiqui R; Cooney KA; Wei JT
    J Urol; 2013 Mar; 189(3):849-53. PubMed ID: 23036981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
    Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
    JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPINK1 protein expression and prostate cancer progression.
    Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
    Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort.
    Hoffmann TJ; Sakoda LC; Shen L; Jorgenson E; Habel LA; Liu J; Kvale MN; Asgari MM; Banda Y; Corley D; Kushi LH; Quesenberry CP; Schaefer C; Van Den Eeden SK; Risch N; Witte JS
    PLoS Genet; 2015 Jan; 11(1):e1004930. PubMed ID: 25629170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.